Table 2.
Overview of the above-mentioned studies investigating the relationship between BDNF and disability.
| Study | Participants | Parameters | Results |
|---|---|---|---|
| Blanco et al. (98) | 224 patients with MS patients, 177 healthy controls | Effect of Val66Met polymorphism on disease susceptibility and severity | No association of Val66Met polymorphism with disease susceptibility or severity No effect of Val66Met polymorphism on peripheral levels BDNF in a subgroup of 12 patients with MS |
| Dinacci et al. (58) | 45 patients with MS, 34 healthy controls | Association of Val66Met polymorphism with MRI characteristics | Lower grey matter volume in Val66Val patients compared to healthy controls, but not in Val66Met patients compared to healthy controls |
| Giordano et al. (90) | 100 patients with progressive MS | Effects of BDNF and NTRK2 genes on motor recovery | In Val66Met carriers greater motor improvement after rehabilitation |
| Islas-Hernandez et al. (96) | 74 patients with RRMS, 11 patients with SPMS, 88 healthy controls | Association of total Tau and BDNF with disease severity/disability | Increased tau and decreased BDNF in patients with MS Higher total tau in patients with RRMS and higher MSSS and lower EDSS scores, no differences in SPMS and patients with severe MS compared to healthy controls |
| Liguori et al. (49) | 50 patients with RRMS, 50 healthy controls | Effect of Val66Met on MRI characteristics and cognition | Lower grey matter volume in patients withVal66Met polymorphism No association of Val66Met polymorphism with cognition in patients with RRMS and healthy controls |
| Liguori et al. (45) | 36 inactive patients with RRMS and 37 healthy controls | Effect of Val66Met polymorphism and BDNF levels on patients with RRMS over 24 months | Higher BDNF levels in patients with RRMS compared to healthy controls, regardless immunotherapy No correlation of Val66Met polymorphism with clinical or MRI characteristics |
| Lindquist et al. (97) | 951 British MS patients | Association of Val66Met polymorphism with disease susceptibility and disease severity | No association of Val66Met polymorphism with disease susceptibility or clinical course |
| Mero et al. (94) | 2,149 patients with MS, 2747 helathy controls | Association of Val66Met polymorphism with disease susceptibility, demographical and clinical parameters | No association of Val66Met polymorphism with disease susceptibility, sex, age at onset, disease course and severity, cognitive impairment |
| Mirowska-Guzel et al. (101) | 230 patients with RRMS/SPMS and 177 healthy controls | Association of BDNF gene (C270T and G196A) and disease susceptibility and disease progression | Earlier disease onset in male patients with 196G/G than 196G/A genotype Higher disease susceptibility in female patients with as well as 196G/G genotype in male patients with 270C/T genotype |
| Nociti et al. (99) | 209 patients with MS | Association of Val66Met polymorphism with methylation level of the BDNF gene and disability | Association of higher disability/disease progression and hypomethylation of BDNF gene with higher BDNF levels |
| Portaccio et al. (100) | 98 patients with MS | Association of Val66Met polymorphism with disability and cognition | Higher prevalence of Val66Met polymorphism in male patients and patients with greater disability Positive association of Val66Met polymorphism with better cognitive performance and higher EDSS |
| Yalachkov et al. (86) | 36 patients with RRMS, PPMS, CIS | Effect of BDNF on disability and cognition after relapse | Association of disability improvement with higher serum BDNF levels and cognitive improvement with higher BDNF levels in CSF at baseline with a positive correlation between serum BDNF and EDSS improvement and CSF-BDNF with z-score change in cognitive tests |
| Zivadinov et al. (1) | 209 patients with MS (108 with cognitive testing) | Effect of Val66Met polymorphism on brain morphometry and functionality measured by MRI and cognitive testing | Positive association of Val66Met polymorphism with normalized grey matter volume and negative association with T2 lesion volume onyl trend towards a positive |